DGX vs. CRL
Compare and contrast key facts about Quest Diagnostics Incorporated (DGX) and Charles River Laboratories International, Inc. (CRL).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: DGX or CRL.
Key characteristics
| DGX | CRL | |
|---|---|---|
| YTD Return | 19.80% | -8.65% |
| 1Y Return | 24.80% | 27.00% |
| 3Y Return (Ann) | 4.83% | -17.66% |
| 5Y Return (Ann) | 11.88% | 9.46% |
| 10Y Return (Ann) | 12.33% | 13.01% |
| Sharpe Ratio | 1.22 | 0.70 |
| Sortino Ratio | 1.95 | 1.25 |
| Omega Ratio | 1.23 | 1.16 |
| Calmar Ratio | 0.98 | 0.41 |
| Martin Ratio | 4.64 | 1.36 |
| Ulcer Index | 5.25% | 18.80% |
| Daily Std Dev | 20.03% | 36.56% |
| Max Drawdown | -49.46% | -69.81% |
| Current Drawdown | -0.17% | -52.88% |
Fundamentals
| DGX | CRL | |
|---|---|---|
| Market Cap | $17.79B | $11.29B |
| EPS | $7.44 | $8.01 |
| PE Ratio | 21.42 | 27.55 |
| PEG Ratio | 1.86 | 2.84 |
| Total Revenue (TTM) | $9.54B | $4.06B |
| Gross Profit (TTM) | $3.08B | $1.37B |
| EBITDA (TTM) | $1.82B | $924.19M |
Correlation
The correlation between DGX and CRL is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
DGX vs. CRL - Performance Comparison
In the year-to-date period, DGX achieves a 19.80% return, which is significantly higher than CRL's -8.65% return. Over the past 10 years, DGX has underperformed CRL with an annualized return of 12.33%, while CRL has yielded a comparatively higher 13.01% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
DGX vs. CRL - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Quest Diagnostics Incorporated (DGX) and Charles River Laboratories International, Inc. (CRL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
DGX vs. CRL - Dividend Comparison
DGX's dividend yield for the trailing twelve months is around 1.83%, while CRL has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DGX Quest Diagnostics Incorporated | 1.83% | 2.02% | 2.08% | 1.40% | 1.85% | 1.99% | 2.34% | 1.83% | 1.72% | 2.07% | 1.92% | 2.24% |
CRL Charles River Laboratories International, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
DGX vs. CRL - Drawdown Comparison
The maximum DGX drawdown since its inception was -49.46%, smaller than the maximum CRL drawdown of -69.81%. Use the drawdown chart below to compare losses from any high point for DGX and CRL. For additional features, visit the drawdowns tool.
Volatility
DGX vs. CRL - Volatility Comparison
The current volatility for Quest Diagnostics Incorporated (DGX) is 7.59%, while Charles River Laboratories International, Inc. (CRL) has a volatility of 15.62%. This indicates that DGX experiences smaller price fluctuations and is considered to be less risky than CRL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
DGX vs. CRL - Financials Comparison
This section allows you to compare key financial metrics between Quest Diagnostics Incorporated and Charles River Laboratories International, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities